All In Biotech

Drug Trial Radar · NCT04935476

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,000

Planned (sponsor's estimate)

Start

Nov 22, 2021

Primary completion

Mar 31, 2022

Study completion Jul 31, 2022

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Pulmonem Inc.
First posted
Jun 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection. 3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tablets for 21 days, and will be followed up for 7 days after treatment termination for outcome assessment and up to 30 days for safety monitoring.

Conditions

  • COVID-19

Interventions

  • Dapsone 85 mg PO BIDDrug

    Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.

  • Placebo 85 mg PO BIDDrug

    Placebo oral tablet, twice daily for 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite outcome: All cause pre-hospitalization death or all-cause hospitalizationTime frame: 30 days post randomization

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Pulmonary and Medical Specialists

    Phoenix, Arizona · Not yet recruiting

  • Peters Medical Research, LLC

    High Point, North Carolina · Recruiting

  • Temple University Hospital

    Philadelphia, Pennsylvania · Not yet recruiting

  • University of Pittsburgh UPMC

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Principle Research Solutions

    Spokane, Washington · Recruiting

  • Inspiration Research Limited

    Toronto, Ontario, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.